Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBIT (2020 - 2025)

Oncology Institute (TOI) has disclosed EBIT for 6 consecutive years, with -$8.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 41.86% year-over-year to -$8.1 million, compared with a TTM value of -$41.1 million through Sep 2025, up 35.24%, and an annual FY2024 reading of -$60.1 million, up 21.94% over the prior year.
  • EBIT was -$8.1 million for Q3 2025 at Oncology Institute, up from -$11.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$1.1 million in Q2 2021 and bottomed at -$40.8 million in Q4 2021.
  • Average EBIT over 5 years is -$15.4 million, with a median of -$14.9 million recorded in 2023.
  • The sharpest move saw EBIT tumbled 1897.17% in 2021, then soared 45.32% in 2024.
  • Year by year, EBIT stood at -$40.8 million in 2021, then skyrocketed by 38.58% to -$25.1 million in 2022, then surged by 39.04% to -$15.3 million in 2023, then rose by 21.97% to -$11.9 million in 2024, then soared by 32.48% to -$8.1 million in 2025.
  • Business Quant data shows EBIT for TOI at -$8.1 million in Q3 2025, -$11.2 million in Q2 2025, and -$9.9 million in Q1 2025.